Treatment of advanced colorectal cancer with doxorubicin combined with two potential multidrug-resistance-reversing agents: High-dose oral tamoxifen and dexverapamil

Journal of Cancer Research and Clinical Oncology

Volumn 123, Issue 8, 1997, Pages 452-455

  Weinlander G ^a   Kornek, G ^a   Raderer, M ^a   Hejna, M ^a   Tetzner, C ^b   Scheithauer, W ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Knoll AG   (Germany)

Author keywords

Colorectal cancer; Dexverapamil; Doxorubicin; Multidrug resistance; Tamoxifen

Indexed keywords

DEXVERAPAMIL; DOXORUBICIN; GLYCOPROTEIN P; TAMOXIFEN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BRADYCARDIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; FEMALE; GRANULOCYTOPENIA; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; MALE; MIDDLE AGED; TAMOXIFEN; VERAPAMIL;

EID: 0030739538     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004320050086     Document Type: Article

References (25)

1. Beck WT, Danks MK, Wolverton JS (1994) Resistance of mamillian tumor cells to inhibitors of DNA topoisomerase II. Adv Pharmacol 298:145-169
2. Berman E, Adams M, Duigou-Osterndorf R, Godfrey L, Clarkson B, Andreeff M (1991) Effect of tamoxifen on cell lines displaying the multidrug-resistance phenotype. Blood 77:818-825
3. Chu E, Drake JC, Koeller DM (1991) Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines. Mol Pharmacol 39:136-143
4. Elliott HL, Meredith PA (1993) Dexverapamil: circumventer of multidrug resistance. In: Eichelbaum M, Hirth HP, Schumacher K, Traugott U (eds) Clinical pharmacological studies with R-verapamil. Kluver Hingham, pp 43-50
5. Fabian C, Sternson L, Bennett M (1980) Clinical pharmacology of tamoxifen in patients with breast cancer. Comparison of traditional and loading dose schedules. Cancer Treat Rep 64:765-773
6. Figueredo A, Arnold A, Goodyear M, Findlay B, Neville A, Normandeau R, Jones A (1990) Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer. Cancer 65:1895-1902
7. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I (1987) Expression of a multidrug resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84:265-269
8. German UA, Harding MW (1995) Chemosensitizers to overcome and prevent multidrug resistance? J Natl Cancer Inst 87:1573-1575
9. Grant CE, Valdimarsson G, Hipfner DR (1994) Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54:357-361
10. Herrmann R, Kant E de (1992) Dexverapamil: circumventer of multidrug resistance. In: Eichelbaum M, Hirth HP, Schumacher K, Traugott U (eds) Modulation of multidrug resistance (MDR) by R-verapamil and P-glycoprotein expression in human colon carcinoma xenotransplants. Kluver, Hingham, pp 39-42
11. Lai GM, Chen YN, Mickley LA, Fojo AT, Bates SE (1991) P-glycoprotein expression and schedule dependence of Adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer 49:696-703
12. Mentges B, Gutt CN, Bülow M (1990) Zum Steroidhormonrezeptorstatus kolorektaler Karzinome. Onkologie 13:13-21
13. Mülder HS, Pinedo HM, Timmer AT, Ramanath Rao B, Lankelma J (1996) Multidrug resistance-modifying components in human plasma with potential clinical significance. J Exp Ther Oncol 1:13-22
14. Oudard S, Thierry A, Jorgenson T (1991) Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes. Cancer Chemother Pharmacol 28:259-265
15. Pearson JW, Fogler WE, Volker K, Usui N, Goldenberg SK, Gruys E, Riggs CW, Komschlies K, Wiltrout RH, Tsuruo T, Pastan I, Gottesman MM, Longo DL (1991) Reversal of drug resistance in human colon cancer xenografts expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody. J Natl Cancer Inst 83:1386-1391
16. Pinedo HM, Giaccone G (1995) P-glycoprotein - a marker of cancer-cell behavior. N Engl J Med 333:1417-1419
17. Raderer M, Scheithauer W (1993) Clinical trials of agents that reverse multidrug resistance. Cancer 72:3553-3563
18. Ramu A, Glaubiger D, Fuks Z (1984) Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. Cancer Res 44:4392-4395
19. Roninson IB, Chin JE, Choi KG, Gros P, Housman DE, Fojo A, Sehn D, Gottesman MM, Pastan I (1986) Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 83:4538-4542
20. Rothenberg ML, Mickley L, Cole D, Balis F, Tsuro T, Poplack D, Fojo A (1989) Expression of the mdr-1/P-170 gene in patients with acute lymphoblastic leukemia. Blood 74:1388-1393
21. Scheithauer W, Kornek G, Kastner J, Raderer M, Locker G, Depisch D, Pidlich J, Tetzner C (1993) Phase II study of D-verapamil and doxorubicin in patients with metastatic colorectal cancer. Eur J Cancer 29A:2337-2338
22. Sela S, Husain SR, Pearson JW, Longo DL, Rahman A (1995) Reversal of resistance in human colon cancer cells expressing the human MDR1 gene by liposomes in combination with monoclonal antibody or verapamil. J Natl Cancer Inst 87:123-128
23. Stein U, Walther W, Shoemaker RH (1996) Reversal of multidrug resistance by transduction of cytokine genes into human colon carcinoma cells. J Natl Cancer Inst 88:1383-1392
24. Trump DL, Smith DC, Ellis PG, Rogers MP, Schold C, Winer EP, Panella TJ, Jordan VC, Fine RL (1992) High-dose oral tamoxifen, a potential multidrug resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 84:1811-1816
25. Weinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszag JR, Klusens LF, Grogan TM, Saclarides TJ, Rononson IB, Coon JS (1991) Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51:2720-2726